Can hi-jacking hypoxia inhibit extracellular vesicles in cancer?

Drug Discov Today. 2018 Jun;23(6):1267-1273. doi: 10.1016/j.drudis.2018.03.006. Epub 2018 Mar 22.

Abstract

Increasing evidence indicates that extracellular vesicles (EVs) are key players in undesirable cell-cell communication in cancer. However, the release of EVs is not unique to cancer cells; normal cells release EVs to perform physiological roles. Thus, selective inhibition of EV release from cancer cells is desirable. Hypoxia contributes to tumour development and aggressiveness. EV quantities and thus undesirable communications are substantially increased in hypoxia. Targeting hypoxia could selectively inhibit EV release from tumour cells without disturbing physiologically relevant EVs. The unfavourable association between hypoxia and EV release is evident in multiple tumour types; therefore, targeting hypoxia could have a broad therapeutic benefit.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Cell Movement
  • Extracellular Vesicles / drug effects*
  • Humans
  • Hypoxia / drug therapy*
  • Hypoxia / pathology
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neoplasms / pathology
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / pathology

Substances

  • Antineoplastic Agents